CSIMarket Company Name, Ticker, Industry, else..
 
Exicure Inc   (NASDAQ: XCUR)
 
Price: $1.2850 $-0.05 -3.383%
Day's High: $1.4193999767303467 Week Perf: -8.21 %
Day's Low: $ 1.28 30 Day Perf: -10.14 %
Volume (M): 6,804 52 Wk High: $ 9.48
Volume (M$): $ 0 52 Wk Avg: $3.62
Open: $1.36 52 Wk Low: $1.05



 Market Capitalization (Millions $) 8
 Shares Outstanding (Millions) 6
 Employees 8
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0

Business Description


Exicure Inc is a clinical-stage biotechnology company that specializes in developing a new class of immunomodulatory and gene regulating therapies based on its proprietary Spherical Nucleic Acid (SNA) technology. The company's technology platform enables the development of novel therapeutics that can penetrate cells more effectively and enable the regulation of gene expression. Exicure uses its SNA technology to target a range of diseases including inflammatory disorders, genetic diseases, and oncology. The company is focused on advancing its pipeline of candidates through preclinical and clinical trials, with the ultimate goal of bringing innovative treatments to patients in need.


   Company Address: 400 Seaport Court Redwood City 94063 CA
   Company Phone Number: 673-1700   Stock Exchange / Ticker: NASDAQ XCUR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARCT        24% 
IONS   -15.94%    
PFE        0.34% 
PTCT        0.19% 
RCUS   -1.3%    
SRPT   -1.02%    
• View Complete Report
   



Business Update

“Exicure’s Nasdaq Nexus Compliance Challenges and the Path to Recovery in Biotech,

Published Thu, Sep 19 2024 12:47 AM UTC

: In the fast-paced world of pharmaceutical innovation, maintaining a robust presence on the financial markets is crucial. Exicure, Inc. a biotechnology company pioneering the development of therapies based on its proprietary spherical nucleic acid (SNA) technology, has recently found itself under the scrutiny of Nasdaq. This article interprets Exicure s recent notices fro...
Business Update

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Published Wed, Sep 18 2024 10:56 PM UTC

Exicure, Inc. Receives Nasdaq Hearing Panel Extension Amidst Financial Challenges and Improved ROA RankingExicure, Inc. recently announced that it has received an extension from the Nasdaq Hearings Panel as the company navigates significant financial challenges. For the 12 months ending in the second quarter of 2024, Exicure recorded a cumulative net loss of $8 million, lea...
Business Update

Exicure, Inc. Faces Nasdaq Delisting as It Delays Filing Form 10-K

Published Fri, May 24 2024 12:15 AM UTC

Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company focused on developing nucleic acid-based therapeutics, has recently received a delisting determination notice from The Nasdaq Stock Market LLC (Nasdaq). The notice was issued due to the company s failure to file its Form 10-K for the year ended December 31, 2023, in accordance with Nasdaq Listing Rule 5250(...
Business Update

Exicure, Inc. Faces Nasdaq Delisting Determination Due to Delayed Filing of Form 10-K

Published Thu, May 23 2024 9:15 PM UTC

In a recent development, Exicure, Inc. (Nasdaq: XCUR), a renowned biotechnology company with a focus on developing nucleic acid therapeutics, has received a delisting determination notice from The Nasdaq Stock Market LLC (Nasdaq). The company has failed to submit its Form 10-K for the year ended December 31, 2023, which is in violation of Nasdaq Listing Rule 5250(c)(1). This...
Product Service News

Exicure, Inc. and Bluejay Therapeutics Join Forces to Develop Revolutionary Hepatitis C Treatment

Published Mon, Feb 5 2024 9:01 PM UTC

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of HepatitisCHICAGO - Exicure, Inc. (NASDAQ:XCUR), a renowned developer of nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company specializing in viral and liver diseases, have recently announced a sig...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 8.38
PEG (TTM) -

Financial Strength Current
Quick Ratio -
Working Capital Ratio 0.43
Leverage Ratio (MRQ) 10.67
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.13 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value 0.15 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,035,500
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.